Jordan Mast
Medical · Denver, CONPI 1518211051
Payments from drug & device makers
Across 2,516 payments — averaging $98.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$114K
- Eisai Inc.$37K
- Lilly USA, LLC$25K
- Pfizer$14K
- Axsome Therapeutics, Inc.$8K
- Lundbeck LLC$6K
- plus $43K from 54 others
Across 2 payments — averaging $555.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1K
What the payments were for
- Consulting fees$39,04816%
- Speaking & faculty fees$136,79055%
- Travel & lodging$16,1947%
- Food & beverage$54,76122%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$246,844 in reported general payments places this provider in the 95th percentile of 766 medical providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 14 | $459,603 |
| Emgality PenGalcanezumab-Gnlm | 126 | $97,360 |
| QuliptaAtogepant | 66 | $75,677 |
| Nurtec OdtRimegepant Sulfate | 49 | $64,838 |
| UbrelvyUbrogepant | 41 | $60,144 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $55,190 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $37,215 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 27 | $22,080 |
| BotoxOnabotulinumtoxina | 16 | $21,317 |
| AptiomEslicarbazepine Acetate | 14 | $17,128 |
| RytaryCarbidopa/Levodopa | 14 | $16,641 |
| Rasagiline Mesylate | 19 | $9,450 |
| Gabapentin | 217 | $3,658 |
| Levetiracetam | 68 | $2,605 |
| Lacosamide | 31 | $2,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt | $13,635 | $524,44163 claims |
| AbbVieQulipta, Ubrelvy, Botox | $113,862 | $157,138123 claims |
| Amneal Pharmaceuticals LLCRytary | $186 | $16,64114 claims |
| Upsher-smith Laboratories LLCTopiramate | $123 | $1,30386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 766 medical providers in Colorado.
Other medical in Denver
- Daniel TaylorDenver$67K
- Ryan MersonDenver$9K
- Christen KutzColorado Springs$2.4M
- Amanda MixonFort Collins$342K
- Kristin RyggColorado Springs$255K
- John NovakAurora$173K
- Michelle BarnettColorado Springs$138K
- Michael JacobsonFort Collins$131K
- Lindsey TunstallAurora$87K
- Jennifer NafzigerHighlands Ranch$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.